Con motivo del Día Mundial del Alzheimer, hablamos con Marta Barrachina, fundadora y directora general de ADmit Therapeutics, uno de nuestros socios que busca un diagnóstico precoz a esta enfermedad...
Despite the Covid-19 pandemic, 2020 has been a great year for ADmit Therapeutics, a spin-off from Bellvitge Biomedical Research Institute (IDIBELL, in Barcelona) born at the end of 2017 and leaded by ...
La spin-of del IDIBELL, creada en 2017 y con sede en L'Hospitalet de Llobregat, es una de las 36 empresas seleccionadas de entre las 1.406 solicitudes recibidas en la convocatoria EIC Accelerator del ...
The SARS-CoV-2 pandemic that is hitting many countries has clearly affected the medical start-up and spin-off ecosystem. After talking to some of the companies we support we have seen that it has not ...
ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnost...
ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnost...